Latest Ratios: P/E Ratio -2.1x · EV/EBITDA N/A · ROE -99.7%. (2005–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $24M | $21M | $20M | $13M | $22M | $51M | $42M | $17M | $29M | $81M | $92M |
| Enterprise Value | $23M | $20M | $16M | $5M | $8M | $30M | $29M | $15M | $21M | $70M | $77M |
| P/E Ratio → | -2.14 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 2.71 | 2.82 | 1.78 | 0.90 | 0.94 | 1.69 | 1.93 | 1.63 | 1.62 | 3.99 | 4.00 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -99.7% | -99.7% | -63.0% | -45.3% | -30.6% | -34.1% | -83.1% | -58.3% | -45.1% | -47.5% | -39.1% |
| ROA | -87.5% | -87.5% | -55.8% | -42.5% | -30.2% | -32.6% | -72.0% | -51.5% | -37.6% | -32.4% | -26.5% |
| ROIC | -114.0% | -114.0% | -95.5% | -84.8% | -65.4% | -70.2% | -69.6% | -69.7% | -70.8% | -86.4% | -88.6% |
| ROCE | -101.1% | -101.1% | -61.2% | -45.3% | -30.6% | -33.8% | -49.4% | -61.3% | -46.6% | -36.8% | -24.1% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | 0.00 | 0.00 | 0.05 | — | — | 0.19 | 0.37 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.21 | -0.42 | -0.55 | -0.61 | -0.68 | -0.58 | -0.24 | -0.40 | -0.55 | -0.67 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | -165.52 | -9155.26 | -1581.44 | -102.38 | -85.37 | — | -17.03 | -4.51 | -3.59 |
Net cash position: cash ($2M) exceeds total debt ($0)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.28 | 1.28 | 3.66 | 15.81 | 34.92 | 59.30 | 6.49 | 0.99 | 8.30 | 3.28 | 3.62 |
| Quick Ratio | 1.28 | 1.28 | 3.66 | 15.81 | 34.92 | 59.30 | 6.49 | 0.99 | 8.30 | 3.28 | 3.62 |
| Cash Ratio | 1.19 | 1.19 | 3.53 | 15.25 | 34.07 | 58.43 | 6.36 | 0.90 | 8.03 | 3.24 | 3.58 |
| Asset Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $15M | $12M | $12M | $12M | $11M | $6M | $4M | $3M | $3M | $3M |
Imminent liquidity exhaustion
According to recent market data, NNVC trades at a price-to-book ratio of 2.69, which appears to reflect a significant discount compared to established biotech peers, suggesting that investors are pricing the company as a high-risk option on its proprietary platform rather than a fundamental valuation of assets.
The absence of revenue renders traditional P/E or EV/EBITDA multiples inapplicable, forcing a reliance on book value as a proxy for the company's tangible and intangible asset base. This valuation level implies that the market is heavily discounting the probability of clinical success, likely due to the company's precarious cash position and the long-term nature of its R&D pipeline.
As reported in financial statements, the company's ROIC has remained consistently negative over the last ten quarters, with a recent reading of -22.4% in 2026Q1, indicating that the firm is currently destroying rather than compounding invested capital as it funds its clinical development programs.
The negative return on capital is a direct consequence of high R&D expenditures coupled with a complete lack of commercial revenue. This trend suggests that until the company can demonstrate a successful clinical milestone or secure a partnership, the efficiency of its capital deployment will remain structurally impaired.
Based on the most recent quarterly data, the current ratio has declined to 3.17, which, while appearing superficially healthy, masks the reality that the company's absolute cash reserves of $1.56 million are insufficient to sustain its ongoing operational burn rate for more than a few quarters.
The volatility in the current ratio, which has fluctuated from 5.59 in 2024Q2 to 1.06 in 2026Q1, highlights the company's extreme sensitivity to the timing of capital raises. Investors should monitor this metric closely, as any further decline in the current ratio would likely signal an immediate need for dilutive financing to avoid operational insolvency.
As evidenced by the company's financial disclosures, the use of debt-to-equity ratios to assess NNVC's financial health is fundamentally misleading, as the firm's lack of long-term debt obscures the severe operational risk posed by its reliance on equity markets for survival.
Analysts often misapply leverage ratios to pre-revenue biotech firms, failing to recognize that the true 'leverage' here is the dilution risk inherent in the company's capital structure. A more appropriate metric for this business model would be the 'burn-to-milestone' ratio, which evaluates the efficiency of capital usage relative to the progression of clinical trial data.
Includes 30+ ratios · 21 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying NNVC stock.
NanoViricides, Inc.'s current P/E ratio is -2.1x. This places it at the 50th percentile of its historical range.
NanoViricides, Inc.'s return on equity (ROE) is -99.7%. The historical average is -83.1%.
Based on historical data, NanoViricides, Inc. is trading at a P/E of -2.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.